Abstract
Four cases of human immunodeficiency virus (HlV)‐infected patients who developed coronary heart disease (CHD) while under treatment with a protease inhibitor (PI) are described, and the epidemiologic and clinical features of 18 cases reported in the literature are analyzed. Cardiac manifestations mostly included myocardial infarctions. Smoking and hyperlipidemia were the most common risk factors for CHD, reported in 72 and 81% of the patients, respectively. Hypercholesterolemia was observed in 75% of the cases at the time of the cardiovascular event. Ninety percent of the patients with pretreatment normal lipid values experienced a rise in the plasma lipid levels during PI therapy. Although a definite relationship between the development of CHD and HIV Pis can not be made, this analysis suggests that Pi‐induced hyperlipidemia may play a role in accelerating coronary atherosclerosis in patients with concomitant risk factors. Evaluation and control of risk factors for CHD should be performed in each patient for whom treatment with a PI is indicated.
Keywords: human immunodeficiency virus (HIV) infection, acquired immune deficiency syndrome, HIV‐1 protease inhibitor, myocardial infarction, coronary heart disease, dys‐lipidemia
Full Text
The Full Text of this article is available as a PDF (454.0 KB).
References
- 1. Katuda T, Struble K, Piscitelli S: Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm 1998; 55: 233–254 [DOI] [PubMed] [Google Scholar]
- 2. Kaul D, Cineti S, Carver P, Kazanjian PH: HIV protease inhibitors: Advances in therapy and adverse reactions including metabolic complications. Pharmacotherapy 1999; 19: 281–298 [DOI] [PubMed] [Google Scholar]
- 3. Berhens G, Schmidt H, Meyer D, Stoll M, Schimdt RE: Vascular complications associated with the use of HIV protease inhibitors (letter). Lancet 1998; 351: 1958 [DOI] [PubMed] [Google Scholar]
- 4. Eriksson U, Opravil M, Amann F Schaffher A: Is treatment with ritonavir a risk factor for myocardial infarction in HIV‐infected patients? AIDS 1998; 12: 2079–2080 [DOI] [PubMed] [Google Scholar]
- 5. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M: Vascular complications associated with the use of HIV protease inhibitors (letter). Lancet 1998; 351: 1959 [DOI] [PubMed] [Google Scholar]
- 6. Henry K, Melroe H, Huebsh J, Hermundson J, Levine C, Swensen L, Daley J: Severe premature coronary artery disease with protease inhibitors (letter). Lancet 1998; 351: 1328 [DOI] [PubMed] [Google Scholar]
- 7. Jütte A, Salzberger, Franzen C , Römer K, Comely D, Diet F, Diehl V, Fätkenheuer G, Salzberger B: Increased morbidity from myocardial infarction during HIV protease inhibitor treatment (abstr 656). Sixth conference on Retrovirus and Opportunistic Infections. Chicago, January‐February 1999.
- 8. Karmochkine M, Raguin G: Severe coronary artery disease in a young HIV‐infected man with no cardiovascular risk factor who was treated with indinavir (letter). AIDS 1998; 12: 2499 [PubMed] [Google Scholar]
- 9. Khellaf M, Thiébaut M, Caumes E, Bricaire F: Infarctus du myocarde sous antiproteases. PresseMed 1998; 27: 1955–1956 [PubMed] [Google Scholar]
- 10. Vittecoq D, Escaut L, Monsuez J: Vascular complications associated with the use of HTV protease inhibitors (letter). Lancet 1998; 351: 1958 [DOI] [PubMed] [Google Scholar]
- 11. Yunis N, Stone V: Cardiac manifestations of HIV/AIDS. J Acquir Immune Defic Syndr 1998; 18: 145–154 [DOI] [PubMed] [Google Scholar]
- 12. Bharati S, Joshi V, Connors E: Conduction syndrome in children with AIDS. Chest 1989; 96: 406–413 [DOI] [PubMed] [Google Scholar]
- 13. Flum D, Tyras D, Wallack M: Coronary artery bypass in patients with HIV. J Cardiol Surg 1997; 12: 98–101 [DOI] [PubMed] [Google Scholar]
- 14. Joshi V, Pawel B, Conner, Shaker L , Oleske JM, Morrison S, Marin‐Garcia J: Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987; 7: 261–275 [DOI] [PubMed] [Google Scholar]
- 15. Paton P, Tabib A, Loire R, Tete R: Coronary artery lesions and HIV infection. Res Virol 1993; 144: 225–231 [DOI] [PubMed] [Google Scholar]
- 16. Constans J, Pellegrin L, Peuchant E, Dumon MF, Pellegrin I, Sergeant C, Simonoff M, Brossard G, Barbeau P, Fleury H, Clerc M, Leng B, Conri C: Plasma lipids in HIV‐infected patients: A prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416–420 [DOI] [PubMed] [Google Scholar]
- 17. Constans J, Marchand J, Conri C, Peuchant E, Seigneur M, Rispal P, Lasseur C, Pellegrin JL, Leng B: Asymptomatic atherosclerosis in HIV‐positive patients: A case‐control ultrasound study. Ann Med 1995; 27: 683–685 [DOI] [PubMed] [Google Scholar]
- 18. Dube M, Johnson D, Currier J, Leedom JM: Protease inhibitor‐associated hyperglycaemia. Lancet 1997; 350: 713–714 [DOI] [PubMed] [Google Scholar]
- 19. Fernandez‐Miranda C, Pulido F, Carrillo JL, Larumbe S, Gomez Izquierdo T, Ortuno B, Rubio R, Del Palacio A: Lipoprotein alterations in patients with HIV infection: Relation with cellular and humoral immune markers. Clin Chim Act 1998, 274: 63–70 [DOI] [PubMed] [Google Scholar]
- 20. Gonzallez‐Clemente, Miro J , Navarro M, Navarro MP, Zamora L, Vilardell E: High triglyceride levels as a predictor of mortality in AIDS patients. AIDS 1993; 7: 1022–1023 [DOI] [PubMed] [Google Scholar]
- 21. Grunfeld C, Kotler D, Shigenaga J: Circulating interferon‐alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90: 154–162 [PubMed] [Google Scholar]
- 22. Meenan J, Mooney E, Mosquita N, Johnson AH, Collins P, Feely J, Mulcahy FM: The impact of HIV progression on serum lipoproteins. AIDS 1992; 6: 1551–1552 [DOI] [PubMed] [Google Scholar]
- 23. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D: Decreased plasma concentrations of HDL cholesterol in HIV‐infected individuals are associated with immune activation. J Acquir Immune Defic Synd 1994; 71: 1149–1156 [PubMed] [Google Scholar]
- 24. Herskowitz A, Willoughby S, Baughman K: Cardiomyopathy associated with antiretroviral therapy in patients with HTV infection: A report of six cases. Ann Intern Med 1992; 116: 311–313 [DOI] [PubMed] [Google Scholar]
- 25. Lipsky JJ: Abnormal fat accumulation in patients with HIV‐1 infection. Lancet 1998; 351: 847–848 [DOI] [PubMed] [Google Scholar]
- 26. Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidemia and insu‐Iine resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51–F58 [DOI] [PubMed] [Google Scholar]
- 27. Carr A, Samaras K, Chisholm D, Cooper DA: Pathogenesis of HIV‐1‐protease inhibitor‐associated peripheral lipodystrophy, hyperlipi‐daemia, and insuline resistance. Lancet 1998; 352: 1881–1883 [DOI] [PubMed] [Google Scholar]
- 28. Martinez E, Gatell J: Metabolic abnormalities and body fat redistribution in HIV‐1 infected patients: The lipodystrophy syndrome. Curr Opin Infect Dis 1999; 12: 13–19 [DOI] [PubMed] [Google Scholar]
- 29. Walli R, Herford O, Michl GM, Demant T, Jäger H, Dieterle C, Bogner JR, Landgraf R, Goebel FD: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1 infected patients. AIDS 1998; 12: F167–F173 [DOI] [PubMed] [Google Scholar]
- 30. Anderson K, Wilson P, Odell P: An updated coronary risk profile: Statement for health professionals. Circulation 1991; 83: 356–362 [DOI] [PubMed] [Google Scholar]
- 31. Jeppesen J, Hein H, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: An eight‐year follow‐up in the Copenhagen Male Study. Circulation 1998; 97: 1029–1036 [DOI] [PubMed] [Google Scholar]